A nearly unbiased test for individual bioequivalence problems using probability criteria

Journal of Statistical Planning and Inference

Volumn 99, Issue 1, 2001, Pages 41-58

  Wang, Weizhen ^a   Gene Hwang, J T ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Cornell University ^*  (United States)

Author keywords

62F03; 62K99; 62P99; Crossover design; Noncentral t distribution; Power; Type I error

Indexed keywords

EID: 0042408146     PISSN: 03783758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-3758(01)00074-X     Document Type: Article

References (20)

1. Anderson S., Hauck W.W. Consideration of individual bioequivalence. J. Pharmacokinetics Biopharmaceutics. 18:1990;259-273.
2. Anderson S., Hauck W.W. Types of bioequivalence and related statistical considerations. Int. J. Clinical Pharmacology, Therapy Toxicology. 30:1992;181-187.
3. Berger R., Hsu J. Bioequivalence trials, intersection-union tests, and equivalence confidence sets. Statistical Sci. 11:1996;283-319.
4. Chow S.C., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. 1992;Marcel Dekker, Inc., New York.
5. EC-GCP, 1993. Biostatistical methodology in clinical trials in applications for marketing authorization for medical products. CPMP Working Party on Efficiency of Medical Products, Draft Guideline Edition, Brussels.
6. FDA, 1992. FDA guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
7. FDA, 1999. Draft guidance on Average, Population, and Individual Approaches to Establishing Bioequivalence U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 1999, BP.
8. Hwang J.T., Wang W. The validity of the test of individual equivalence ratios (TIER). Biometrika. 84(4):1997;893-900.
9. Liu J.P., Chow S.C. A two one-sided tests procedure for assessment of individual bioequivalence. J. Biopharmaceutical Statist. 7:1997;49-61.
10. Liu J.P., Chow S.C. On Assessment of Bioequivalence in Variability of Bioavailability Studies. Commun. Statist. Part A. 21:1992;2591-2607.
11. Phillips K.F. A log-normal model for individual bioequivalence. J. Biopharmaceutical Statist. 3:1993;185-201.
12. Schall R. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Biometrics. 51:1995;615-626.
13. Schall R., Luus H.G. On population and individual bioequivalence. Statist. Med. 12:1993;1109-1124.
14. Schall, R., Williams, R.L., 1996. Towards a practical strategy for assessing individual bioequivalence. J. Pharmacokinetics Biopharmaceutics 24(1) 133-149 (for FDA individual bioequivalence working group).
15. Sheiner L.B. Bioequivalence revisited. Statist. Med. 11:1992;1777-1788.
16. Wang, W., 1995. On assessment of bioequivalence. Ph.D. thesis, Cornell University.
17. Wang W. Optimal unbiased tests for equivalence in intra-subject variability. J. Amer. Statist. Assoc. 92:1997;1163-1170.
18. Wang W. On testing of individual bioequivalence. J. Amer. Statist. Assoc. 94:1999;880-887.
19. Wellek, S., 1989. Vorschläge zur Reformulierung der statistischen Definition von Bioäquivalenz, Medizinische Informatik und Statistik, Vol. 71, Springer, Berlin, Heidelberg, pp. 95-99.
20. Wellek S. Basing the analysis of comparative bioavailability trials on an individualized statistical definition of equivalence. Biometrical J. 35(1):1993;47-55.